EUVIMEDEUVIMED entdecken
Multizentrische Studie

Glofitamab as a salvage treatment for B‐cell lymphomas in the real world: A multicenter study in Taiwan

Ya-Ting Hsu iD, Shang-Ju Wu, Hsiao-Wen Kao, Sheng-Yen Hsiao, Chun-Kai Liao, Tsai-Yun Chen, Ming-Chung Wang

Cancer · 2024-06 · 130 (11) · 1972-1981

DOI: 10.1002/cncr.35217 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer, online erschienen am 02.02.2024. Verfasst von Ya-Ting Hsu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University…. Hauptthemen laut MEDLINE: Lymphoma, B-Cell, Salvage Therapy, Antibodies, Bispecific. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glofitamab is a bispecific antibody with promise for treating relapsed/refractory B‐cell lymphoma according to a phase 1/2 clinical trial. This study examined its real‐world effectiveness.

Methods

This was an investigator‐initiated, multicenter retrospective study including 34 patients who had relapsed/refractory B‐cell lymphomas after at least three prior lines of therapy and received glofitamab monotherapy in a compassionate use program in Taiwan between January 2021 and October 2022.

Results

At a median follow‐up of 15.9 months, 56% of patients responded to glofitamab and 23% achieved complete remission. Response to the previous line of therapy significantly correlated with response to glofitamab ( p = .020). Most responses were durable; only five out of the 19 responders had documented disease recurrence at the data cutoff date. The estimated progression‐free survival (PFS) was 3.2 months, and the estimated 1‐year PFS was 33% for the entire cohort. PFS was better for responders than nonresponders (median PFS, 16.9 vs. 1.8 months; 1‐year PFS, 60% vs. 0%). Forty‐three cytokine release syndrome (CRS) events were observed, three of which were grade 3; all were manageable without glofitamab discontinuation. No immune effector cell–associated neurotoxicity was reported. Among seven hepatitis B virus (HBV) carriers (six had antiviral prophylaxis) and 14 patients with remote HBV (four had antiviral prophylaxis), no HBV reactivation was observed.

Conclusions

In this real‐world cohort, glofitamab exhibited effectiveness comparable to trial results without excessive CRS or new safety issues. With appropriate prophylaxis, glofitamab‐treated patients with chronic or remote HBV infection are unlikely to experience virus reactivation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, B-CellSalvage TherapyAntibodies, BispecificHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultTaiwanAged, 80 and overProgression-Free SurvivalNeoplasm Recurrence, LocalAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

B‐cell lymphomabispecific antibodyglofitamabreal‐world data

Substanzen

Antibodies, BispecificAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Division of Hematology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
  • Division of Hematology-Oncology, Department of Internal Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan.
  • Division of Hematology-Oncology, Department of Internal Medicine, E-Da Dachang Hospital, I-Shou University, Kaohsiung, Taiwan.
  • Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung-Chang Gang Memorial Hospital, Kaohsiung, Taiwan.

ORCID-Profile: Ya-Ting Hsu

Zitieren

APA

Hsu, Y. T., Wu, S. J., Kao, H. W., Hsiao, S. Y., Liao, C. K., Chen, T. Y., & Wang, M. C. (2024). Glofitamab as a salvage treatment for B‐cell lymphomas in the real world: A multicenter study in Taiwan. Cancer, 130(11), 1972-1981. https://doi.org/10.1002/cncr.35217

Vancouver

Hsu YT, Wu SJ, Kao HW, Hsiao SY, Liao CK, Chen TY, et al. Glofitamab as a salvage treatment for B‐cell lymphomas in the real world: A multicenter study in Taiwan. Cancer. 2024;130(11):1972-1981. doi:10.1002/cncr.35217

BibTeX
@article{Hsu2024,
  author = {Hsu, Ya-Ting and Wu, Shang-Ju and Kao, Hsiao-Wen and Hsiao, Sheng-Yen and Liao, Chun-Kai and Chen, Tsai-Yun and Wang, Ming-Chung},
  title = {Glofitamab as a salvage treatment for B‐cell lymphomas in the real world: A multicenter study in Taiwan},
  journal = {Cancer},
  year = {2024},
  volume = {130},
  number = {11},
  pages = {1972--1981},
  doi = {10.1002/cncr.35217}
}
Kostenlos starten →